Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Radius Health Inc (NASDAQ:RDUS)

45.26
Delayed Data
As of Jul 22
 +3.05 / +7.23%
Today’s Change
24.75
Today|||52-Week Range
79.90
-26.45%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.9B

Company Description

Radius Health, Inc. a biopharmaceutical company, which engages in the discovery and development of therapeutics for the treatment of osteoporosis and other women's health conditions. Its BA058 Injection product is a daily subcutaneous injection of novel synthetic peptide analog of human parathyroid hormone-related protein. The company also develops BA058 Microneedle Patch; RAD1901, a selective estrogen receptor modulator for the treatment of vasomotor symptoms in women entering menopause; and RAD140, a selective androgen receptor modulator. Its initial business was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt and John T. Potts on October 3, 2003. Radius Health was founded on February 4, 2008 and is headquartered in Cambridge, MA.

Contact Information

Radius Health, Inc.
950 Winter Street
Waltham Massachusetts 02451
P:(617) 551-4000
Investor Relations:

Employees

Shareholders

Mutual fund holders43.84%
Other institutional38.73%
Individual stakeholders21.67%

Top Executives

Robert E. WardPresident, Chief Executive Officer & Director
Brian Nicholas HarveyCFO, Secretary, Treasurer & Senior Vice President
Gary HattersleyChief Scientific Officer & Senior Vice President
Lorraine A. FitzpatrickChief Medical Officer
Dinesh PurandareSenior Vice President & Head-Global Oncology